{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:25:07Z","timestamp":1777577107349,"version":"3.51.4"},"reference-count":75,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.xphs.2018.05.022","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T17:50:23Z","timestamp":1528221023000},"page":"2544-2558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Structural Characterization and Formulation Development of a Trivalent Equine Encephalitis Virus-Like Particle Vaccine Candidate"],"prefix":"10.1016","volume":"107","author":[{"given":"Vishal M.","family":"Toprani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Newton","family":"Wahome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshit","family":"Khasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Kueltzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Russell","family":"Middaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangeeta B.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Volkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.xphs.2018.05.022_bib1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.vetmic.2009.08.023","article-title":"Encephalitic alphaviruses","volume":"140","author":"Zacks","year":"2010","journal-title":"Vet Microbiol"},{"issue":"3","key":"10.1016\/j.xphs.2018.05.022_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.cveq.2014.08.009","article-title":"West nile virus and equine encephalitis viruses","volume":"30","author":"Long","year":"2014","journal-title":"Vet Clin North Am Equine Pract"},{"key":"10.1016\/j.xphs.2018.05.022_bib3","series-title":"Viral Infections of Humans","first-page":"123","article-title":"Alphaviruses: equine encephalitis and others","author":"Weaver","year":"2014"},{"key":"10.1016\/j.xphs.2018.05.022_bib4","first-page":"110","article-title":"Zoonoses and communicable diseases common to man and animals","volume":"Vol. 2","author":"Acha","year":"2003"},{"key":"10.1016\/j.xphs.2018.05.022_bib5","first-page":"333","article-title":"Zoonoses and communicable diseases common to man and animals","volume":"Vol. 2","author":"Acha","year":"2003"},{"key":"10.1016\/j.xphs.2018.05.022_bib6","first-page":"365","article-title":"Zoonoses and communicable diseases common to man and animals","volume":"Vol. 2","author":"Acha","year":"2003"},{"key":"10.1016\/j.xphs.2018.05.022_bib7","first-page":"25","article-title":"The 1933 outbreak of infectious equine encephalomyelitis in the eastern states","volume":"14","author":"Giltner","year":"1933","journal-title":"North Am Vet"},{"issue":"2","key":"10.1016\/j.xphs.2018.05.022_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3181\/00379727-31-7066C","article-title":"A\u00a0serological difference between eastern and western equine encephalomyelitis virus","volume":"31","author":"Broeck","year":"1933","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.xphs.2018.05.022_bib9","series-title":"Eastern equine encephalitis","year":"2016"},{"issue":"3","key":"10.1016\/j.xphs.2018.05.022_bib10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4269\/ajtmh.14-0055","article-title":"Current strategic thinking for the development of a trivalent alphavirus vaccine for human use","volume":"91","author":"Wolfe","year":"2014","journal-title":"Am J Trop Med Hyg"},{"issue":"19","key":"10.1016\/j.xphs.2018.05.022_bib11","doi-asserted-by":"crossref","first-page":"9775","DOI":"10.1128\/JVI.00876-10","article-title":"Structure of the recombinant alphavirus western equine encephalitis virus revealed by cryoelectron microscopy","volume":"84","author":"Sherman","year":"2010","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.xphs.2018.05.022_bib12","doi-asserted-by":"crossref","first-page":"D80","DOI":"10.1016\/j.vaccine.2009.07.095","article-title":"Vaccines for Venezuelan equine encephalitis","volume":"27 Suppl 4","author":"Paessler","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2018.05.022_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fmicb.2017.00081","article-title":"Live, attenuated venezuelan equine encephalitis virus vaccine (TC83) causes persistent brain infection in mice with non-functional \u03b1\u03b2 T-cells","volume":"8","author":"Taylor","year":"2017","journal-title":"Front Microbiol"},{"issue":"9959","key":"10.1016\/j.xphs.2018.05.022_bib14","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/S0140-6736(14)61185-5","article-title":"Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial","volume":"384","author":"Chang","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.xphs.2018.05.022_bib15","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1016\/j.xphs.2017.07.019","article-title":"Structural characterization and physicochemical stability profile of a double mutant heat labile toxin protein based adjuvant","volume":"106","author":"Toprani","year":"2017","journal-title":"J\u00a0Pharm Sci"},{"issue":"41","key":"10.1016\/j.xphs.2018.05.022_bib16","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1016\/j.vaccine.2017.03.101","article-title":"Development of a candidate stabilizing formulation for bulk storage of a double mutant heat labile toxin (dmLT) protein based adjuvant","volume":"35","author":"Toprani","year":"2017","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.xphs.2018.05.022_bib17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jps.24211","article-title":"Characterization of an oncolytic herpes simplex virus drug candidate","volume":"104","author":"Kumru","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2018.05.022_bib18","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/pro.2144","article-title":"Improved data visualization techniques for analyzing macromolecule structural changes","volume":"21","author":"Kim","year":"2012","journal-title":"Protein Sci"},{"issue":"1","key":"10.1016\/j.xphs.2018.05.022_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev.ento.49.061802.123422","article-title":"Venezuelan equine encephalitis","volume":"49","author":"Weaver","year":"2003","journal-title":"Annu Rev Entomol"},{"key":"10.1016\/j.xphs.2018.05.022_bib20","first-page":"45S","article-title":"Appendix 2","volume":"49","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.xphs.2018.05.022_bib21","series-title":"Biological Macromolecules: UV-visible Spectrophotometry","author":"Schmid","year":"2001"},{"issue":"2","key":"10.1016\/j.xphs.2018.05.022_bib22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.virol.2010.08.015","article-title":"A\u00a0simple and general method for determining the protein and nucleic acid content of viruses by UV absorbance","volume":"407","author":"Porterfield","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.xphs.2018.05.022_bib23","series-title":"Molecular Cloning: A Laboratory Manual","author":"Sambrook","year":"2001"},{"key":"10.1016\/j.xphs.2018.05.022_bib24","first-page":"384","article-title":"Isolierung und kristallisation des garungsferments enolase","volume":"310","author":"Warburg","year":"1941","journal-title":"Biochem z"},{"issue":"10","key":"10.1016\/j.xphs.2018.05.022_bib25","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1002\/jps.22618","article-title":"Multidimensional methods for the formulation of biopharmaceuticals and vaccines","volume":"100","author":"Maddux","year":"2011","journal-title":"J\u00a0Pharm Sci"},{"issue":"27","key":"10.1016\/j.xphs.2018.05.022_bib26","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1016\/S0264-410X(01)00098-6","article-title":"Impact of osmolality on burning sensations during and immediately after intramuscular injection of 0.5 ml of vaccine suspensions in healthy adults","volume":"19","author":"Nony","year":"2001","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.xphs.2018.05.022_bib27","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.xphs.2016.09.034","article-title":"If euhydric and isotonic do not work, what are acceptable pH and osmolality for parenteral drug dosage forms?","volume":"106","author":"Roethlisberger","year":"2017","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2018.05.022_bib28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/bit.25159","article-title":"Bioengineering virus-like particles as vaccines","volume":"111","author":"Lua","year":"2014","journal-title":"Biotechnol Bioeng"},{"issue":"10","key":"10.1016\/j.xphs.2018.05.022_bib29","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Rold\u00e3o","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.xphs.2018.05.022_bib30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12033-012-9598-4","article-title":"Construction and characterization of virus-like particles: a review","volume":"53","author":"Zeltins","year":"2013","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.xphs.2018.05.022_bib31","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nbt1030","article-title":"Characterizing biological products and assessing comparability following manufacturing changes","volume":"22","author":"Chirino","year":"2004","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.xphs.2018.05.022_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.biologicals.2012.10.001","article-title":"Analytical lessons learned from selected therapeutic protein drug comparability studies","volume":"41","author":"Federici","year":"2013","journal-title":"Biologicals"},{"issue":"1","key":"10.1016\/j.xphs.2018.05.022_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biologicals.2010.08.004","article-title":"Comparability assessments of process and product changes made during development of two different monoclonal antibodies","volume":"39","author":"Lubiniecki","year":"2011","journal-title":"Biologicals"},{"issue":"3","key":"10.1016\/j.xphs.2018.05.022_bib34","doi-asserted-by":"crossref","first-page":"734","DOI":"10.4161\/hv.27316","article-title":"Characterization of virus-like particles in GARDASIL\u00ae by cryo transmission electron microscopy","volume":"10","author":"Zhao","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.xphs.2018.05.022_bib35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1586\/erv.12.151","article-title":"Virus-like particles for the prevention of human papillomavirus-associated malignancies","volume":"12","author":"Wang","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.xphs.2018.05.022_bib36","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0006-3495(91)82181-6","article-title":"Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction","volume":"60","author":"Baker","year":"1991","journal-title":"Biophys J"},{"issue":"6","key":"10.1016\/j.xphs.2018.05.022_bib37","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0264-410X(96)00239-3","article-title":"Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity","volume":"15","author":"Diminsky","year":"1997","journal-title":"Vaccine"},{"issue":"41","key":"10.1016\/j.xphs.2018.05.022_bib38","doi-asserted-by":"crossref","first-page":"14783","DOI":"10.1073\/pnas.0505062102","article-title":"Hepatitis B small surface antigen particles are octahedral","volume":"102","author":"Gilbert","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.xphs.2018.05.022_bib39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/jps.23801","article-title":"Preformulation study of highly purified inactivated polio vaccine, serotype 3","volume":"103","author":"Qi","year":"2014","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2018.05.022_bib40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.addr.2014.10.023","article-title":"Formulation and stabilization of recombinant protein based virus-like particle vaccines","volume":"93","author":"Jain","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2018.05.022_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fphar.2014.00039","article-title":"Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles","volume":"5","author":"Alsenaidy","year":"2014","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2018.05.022_bib42","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.xphs.2015.10.014","article-title":"Correlating the impact of well-defined oligosaccharide structures on physical stability profiles of IgG1-Fc glycoforms","volume":"105","author":"More","year":"2016","journal-title":"J\u00a0Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2018.05.022_bib43","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/jps.20157","article-title":"Development of stable liquid formulations for adenovirus-based vaccines","volume":"93","author":"Evans","year":"2004","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2018.05.022_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jps.20675","article-title":"A\u00a0rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine","volume":"96","author":"Peek","year":"2007","journal-title":"J\u00a0Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2018.05.022_bib45","doi-asserted-by":"crossref","first-page":"e0118963","DOI":"10.1371\/journal.pone.0118963","article-title":"Effect of chemical stabilizers on the thermostability and infectivity of a representative panel of freeze dried viruses","volume":"10","author":"Pastorino","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.xphs.2018.05.022_bib46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1006\/biol.1998.0157","article-title":"Stability of 17D yellow fever virus vaccine using different stabilizers","volume":"26","author":"Adebayo","year":"1998","journal-title":"Biologicals"},{"issue":"43","key":"10.1016\/j.xphs.2018.05.022_bib47","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.1016\/j.vaccine.2011.07.054","article-title":"Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines","volume":"29","author":"Wiggan","year":"2011","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.xphs.2018.05.022_bib48","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1002\/jps.22563","article-title":"Formulation and stabilization of francisella tularensis live vaccine strain","volume":"100","author":"Ohtake","year":"2011","journal-title":"J\u00a0Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2018.05.022_bib49","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/10837450701481157","article-title":"Protein stability during freezing: separation of stresses and mechanisms of protein stabilization","volume":"12","author":"Bhatnagar","year":"2007","journal-title":"Pharm Dev Technol"},{"issue":"5","key":"10.1016\/j.xphs.2018.05.022_bib50","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","article-title":"Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies","volume":"42","author":"Kumru","year":"2014","journal-title":"Biologicals"},{"issue":"1-2","key":"10.1016\/j.xphs.2018.05.022_bib51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0264-410X(99)00149-8","article-title":"Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles","volume":"18","author":"Diminsky","year":"1999","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.xphs.2018.05.022_bib52","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1021\/js980140v","article-title":"Effects of tween 80 and sucrose on acute short-term stability and long-term storage at\u00a0\u221220 \u00b0C of a recombinant hemoglobin","volume":"87","author":"Kerwin","year":"1998","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2018.05.022_bib53","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11095-006-9131-1","article-title":"Sorbitol crystallization can lead to protein aggregation in frozen protein formulations","volume":"24","author":"Piedmonte","year":"2007","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2018.05.022_bib54","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11095-010-0343-z","article-title":"Frozen state storage instability of a monoclonal antibody: aggregation as a consequence of trehalose crystallization and protein unfolding","volume":"28","author":"Singh","year":"2011","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2018.05.022_bib55","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/jps.23473","article-title":"Frozen-state storage stability of a monoclonal antibody: aggregation is impacted by freezing rate and solute distribution","volume":"102","author":"Miller","year":"2013","journal-title":"J\u00a0Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2018.05.022_bib56","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1023\/A:1016177404647","article-title":"Crystallization behavior of mannitol in frozen aqueous solutions","volume":"19","author":"Cavatur","year":"2002","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.xphs.2018.05.022_bib57","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/jps.22820","article-title":"Applications of differential scanning calorimetry for thermal Stability analysis of proteins: qualification of DSC","volume":"101","author":"Wen","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2018.05.022_bib58","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.abb.2012.09.008","article-title":"Differential scanning calorimetry as a tool for protein folding and stability","volume":"531","author":"Johnson","year":"2013","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"10.1016\/j.xphs.2018.05.022_bib59","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vaccine.2012.10.083","article-title":"Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development","volume":"31","author":"Kushnir","year":"2012","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.xphs.2018.05.022_bib60","doi-asserted-by":"crossref","first-page":"e0143071","DOI":"10.1371\/journal.pone.0143071","article-title":"A\u00a0novel virus-like particle based vaccine platform displaying the placental malaria antigen VAR2CSA","volume":"10","author":"Thrane","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.xphs.2018.05.022_bib61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4161\/hv.3.4.4309","article-title":"Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice","volume":"3","author":"Caulfield","year":"2007","journal-title":"Hum Vaccin"},{"issue":"1","key":"10.1016\/j.xphs.2018.05.022_bib62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/imm.12202","article-title":"Immunogenicity of recombinant human bocavirus-1,2 VP2 gene virus-like particles in mice","volume":"142","author":"Deng","year":"2014","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.xphs.2018.05.022_bib63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/2051013613480144","article-title":"Working together: interactions between vaccine antigens and adjuvants","volume":"1","author":"Fox","year":"2013","journal-title":"Ther Adv Vaccines"},{"issue":"3","key":"10.1016\/j.xphs.2018.05.022_bib64","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0169-409X(98)00008-8","article-title":"Aluminum compounds as vaccine adjuvants","volume":"32","author":"Gupta","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.xphs.2018.05.022_bib65","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0264-410X(95)80009-3","article-title":"Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants","volume":"13","author":"Al-Shakhshir","year":"1995","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.xphs.2018.05.022_bib66","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/jps.20762","article-title":"Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants","volume":"96","author":"Peek","year":"2007","journal-title":"J\u00a0Pharm Sci"},{"issue":"14","key":"10.1016\/j.xphs.2018.05.022_bib67","doi-asserted-by":"crossref","first-page":"13406","DOI":"10.1074\/jbc.M500687200","article-title":"Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens","volume":"280","author":"Jones","year":"2005","journal-title":"J\u00a0Biol Chem"},{"issue":"9","key":"10.1016\/j.xphs.2018.05.022_bib68","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/jps.21498","article-title":"Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solution","volume":"98","author":"Vessely","year":"2009","journal-title":"J\u00a0Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2018.05.022_bib69","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1128\/CVI.00174-12","article-title":"Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant","volume":"19","author":"Wagner","year":"2012","journal-title":"Clin Vacc Immunol"},{"issue":"5","key":"10.1016\/j.xphs.2018.05.022_bib70","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1586\/14760584.2014.907528","article-title":"Physicochemical and functional characterization of vaccine antigens and adjuvants","volume":"13","author":"Dey","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.xphs.2018.05.022_bib71","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1006\/jcis.1997.5230","article-title":"Elutability of proteins from aluminum-containing vaccine adjuvants by treatment with surfactants","volume":"197","author":"Rinella","year":"1998","journal-title":"J\u00a0Colloid Interface Sci"},{"issue":"1","key":"10.1016\/j.xphs.2018.05.022_bib72","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1081\/PDT-120017526","article-title":"Effect of the degree of phosphate substitution in aluminum hydroxide adjuvant on the adsorption of phosphorylated proteins","volume":"8","author":"Iyer","year":"2003","journal-title":"Pharm Dev Technol"},{"issue":"11","key":"10.1016\/j.xphs.2018.05.022_bib73","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.vaccine.2003.10.023","article-title":"Mechanism of adsorption of hepatitis B surface antigen by aluminum hydroxide adjuvant","volume":"22","author":"Iyer","year":"2004","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.xphs.2018.05.022_bib74","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/14760584.6.5.685","article-title":"Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation","volume":"6","author":"Hem","year":"2007","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.xphs.2018.05.022_bib75","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0264-410X(01)00313-9","article-title":"Change in the degree of adsorption of proteins by aluminum-containing adjuvants following exposure to interstitial fluid: freshly prepared and aged model vaccines","volume":"20","author":"Shi","year":"2001","journal-title":"Vaccine"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918303277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918303277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:25:02Z","timestamp":1758360302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354918303277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0022354918303277"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2018.05.022","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural Characterization and Formulation Development of a Trivalent Equine Encephalitis Virus-Like Particle Vaccine Candidate","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2018.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}